Although market demand remains uneven in some ATMP segments, European CDMOs continue investing in:
- cell & gene therapy
- viral vectors
- plasmid DNA flexible modular manufacturing
Key Drivers:
- Growth in gene therapy pipelines
- Increased investment into rare disease therapies
- Growing demand for viral vector capacity
- Manufacturing scalability challenges
- Demand for GMP expertise in ATMPs
Leading European ATMP-Focused CDMOs:
- Oxford Biomedica
- RoslinCT
- Viralgen
- Exothera
- AGC Biologics
- Cognate BioServices
- WuXi Advanced Therapies
- Minaris Regenerative Medicine
- Rentschler ATMP
- Charles River Laboratories
What This Means for Sponsors
The European ATMP ecosystem is shifting toward specialized CDMOs capable of supporting both early clinical development and eventual commercial scale-up.
